Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Neoplasms × capivasertib × Clear all

Phase

Phase 2 1 Phase 1/2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Breast Neoplasms 6 Triple Negative Breast Neoplasms 2 Recurrence 1 Prostatic Neoplasms 1 Non-small Cell Lung Cancer Metastatic 1 Neoplasms 1 Neoplasm Metastasis 1 Lymphoma, Mantle-Cell 1 Lymphoma, Follicular 1 Lymphoma, B-Cell, Marginal Zone 1 Lymphoma, B-Cell 1 Lung Neoplasms 1 Carcinoma, Squamous Cell 1 Carcinoma, Non-Small-Cell Lung 1 CCCA Assessed by Ki67 Drop Below <2.7% From Baseline 1 Advanced Gastric Cancer 1 Advanced Breast Cancer 1 Adenocarcinoma 1

Interventions

Bevacizumab 45 Gemcitabine 44 Cyclophosphamide 39 Carboplatin 37 Docetaxel 34 Fluorouracil 32 Cisplatin 32 Paclitaxel 31 pembrolizumab 28 Oxaliplatin 25 Radiotherapy 24 Irinotecan 23 Leucovorin 22 Capecitabine 22 Dexamethasone 21 Cetuximab 21 Nivolumab 19 Pemetrexed 18 Drug Therapy 18 Doxorubicin 18 Erlotinib Hydrochloride 17 Trastuzumab 15 Rituximab 15 Prednisone 15 durvalumab 14 atezolizumab 13 Sorafenib 13 fludarabine 12 Lapatinib 12 Everolimus 12

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02576444 2022-12-28

OLAPCO

Yale University

Phase 2 Terminated

67 enrolled 10 charts

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡